TY - JOUR
T1 - Effects of growth hormone and/or sex steroid administration on whole-body protein turnover in healthy aged women and men
AU - Huang, Xin
AU - Blackman, Marc R.
AU - Herreman, Karen
AU - Pabst, Katharine M.
AU - Harman, S. Mitchell
AU - Caballero, Benjamin
PY - 2005/9
Y1 - 2005/9
N2 - Aging is associated with reduced activities of the growth hormone (GH), insulin-like growth factor I (IGF-I), and sex steroid axes, and with decreased lean body mass and protein synthesis. Using a randomized, double-blinded, placebo-controlled design, we studied the effects of 6 months of administration of GH alone, sex hormone alone (hormone replacement therapy in women, testosterone enanthate [T] in men), or GH plus sex hormone on protein turnover in healthy men (n = 60) and women (n = 43), aged 65 to 88 years (mean, 71 ± 4.4 years). Growth hormone administration significantly increased IGF-I levels in both sexes, more markedly in men. Sex steroid administration increased the levels of estrogen and testosterone in women and men, respectively (P = .05). Protein turnover was measured before and after the 26-week treatment period by means of a primed, constant l-[1-13C]leucine infusion. In men, GH plus T administration increased leucine flux from 80.2 ± 2.8 to 93.6 ± 4.2 μmol·h-1·kg-1 (P = .02). Leucine oxidation did not change significantly after hormone treatment in either sex. Growth hormone treatment led to nonsignificant upward trends in nonoxidative leucine disposal in men (9.1 ± 5.2 mol·h -1·kg-1) and women (7.6 ± 7.1 mol·h-1·kg-1). Among all groups combined, changes in nonoxidative leucine disposal were directly related to those of serum IGF-I level (r = 0.248, P < .02). Whole-body protein turnover increased in GH plus T-treated men (0.6 ± 0.2 g protein·kg -1·d-1; P < .01). These data suggest that low-dose GH administration increases protein synthesis in healthy aged women and men, and that the coadministration of testosterone plus GH enhances this effect in elderly men.
AB - Aging is associated with reduced activities of the growth hormone (GH), insulin-like growth factor I (IGF-I), and sex steroid axes, and with decreased lean body mass and protein synthesis. Using a randomized, double-blinded, placebo-controlled design, we studied the effects of 6 months of administration of GH alone, sex hormone alone (hormone replacement therapy in women, testosterone enanthate [T] in men), or GH plus sex hormone on protein turnover in healthy men (n = 60) and women (n = 43), aged 65 to 88 years (mean, 71 ± 4.4 years). Growth hormone administration significantly increased IGF-I levels in both sexes, more markedly in men. Sex steroid administration increased the levels of estrogen and testosterone in women and men, respectively (P = .05). Protein turnover was measured before and after the 26-week treatment period by means of a primed, constant l-[1-13C]leucine infusion. In men, GH plus T administration increased leucine flux from 80.2 ± 2.8 to 93.6 ± 4.2 μmol·h-1·kg-1 (P = .02). Leucine oxidation did not change significantly after hormone treatment in either sex. Growth hormone treatment led to nonsignificant upward trends in nonoxidative leucine disposal in men (9.1 ± 5.2 mol·h -1·kg-1) and women (7.6 ± 7.1 mol·h-1·kg-1). Among all groups combined, changes in nonoxidative leucine disposal were directly related to those of serum IGF-I level (r = 0.248, P < .02). Whole-body protein turnover increased in GH plus T-treated men (0.6 ± 0.2 g protein·kg -1·d-1; P < .01). These data suggest that low-dose GH administration increases protein synthesis in healthy aged women and men, and that the coadministration of testosterone plus GH enhances this effect in elderly men.
UR - http://www.scopus.com/inward/record.url?scp=23944520856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23944520856&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2005.03.023
DO - 10.1016/j.metabol.2005.03.023
M3 - Article
C2 - 16125527
AN - SCOPUS:23944520856
SN - 0026-0495
VL - 54
SP - 1162
EP - 1167
JO - Metabolism: clinical and experimental
JF - Metabolism: clinical and experimental
IS - 9
ER -